Focus Taiwan
Date: 2017/03/07
By: Wen Kuei-hsiang and Y.F. Low

Taipei, March 7 (CNA) The Food and Drug Administration (FDA) on Tuesday ordered a recall of all batches of the lipid-lowering drug Crestor from hospitals, clinics and pharmacies, after a second batch of the medication was found to have been mixed with counterfeit drugs.

The FDA has requested Crestor’s manufacturer, AstraZeneca, to help replace the counterfeits, and the company will also conduct a comprehensive examination in regional hospitals and medical centers, said FDA Director-General Wu Shou-mei (吳秀梅).

The administration first confirmed on March 4 that batch number MV503 of Crestor 10 mg tablets had been mixed with counterfeits containing atorvastatin, a cheaper lipid-lowering ingredient, instead of rosuvastatin.    [FULL  STORY]